Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.37 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247520 | 0.87 | ABCB1 (0.41) | KMT2AHCRTR2HCRTR1ABCB1NPC1 | |
| SCHEMBL4247541 | 0.85 | HCRTR2 (0.41) | MAPTKMT2AALDH1A1SMN1; SMN2HCRTR2 | |
| Hydrochloric Acid SCHEMBL4247360 | 0.80 | CHRM2 (0.45) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4247358 | 0.80 | HCRTR2 (0.41) | MAPTKMT2AALDH1A1SMN1; SMN2HCRTR2 | |
| SCHEMBL4253487 | 0.80 | MAPT (0.41) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4243341 | 0.76 | MAPT (0.44) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3155094 | 0.69 | CHRM2 (0.47) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4249161 | 0.69 | CHRM2 (0.46) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4247516 | 0.67 | ABCB1 (0.40) | MAPTKMT2AMEN1ABCB1 | |
| SCHEMBL3145228 | 0.66 | KMT2A (0.55) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076325-B2 | 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20090069296-A1 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069296-A1 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | OXER1, NR1H3, OXSR1 | MAPT 2717/4885KMT2A 1570/4885MEN1 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.